Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05875233
Other study ID # 20318
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date April 13, 2023
Est. completion date April 15, 2024

Study information

Verified date February 2024
Source Zenchi, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a virtual, open-label, 2-armed study that will last 6 months. All participants will take the supplements daily and complete questionnaires at baseline and at the end of weeks 4, 8, 12, 16, 20, and 24 (study may be concluded at week 20 if results are seen earlier). The study will involve 70 participants with polycystic ovary syndrome (PCOS), 35 who are on hormonal birth control, and 35 who are not. A subgroup of 20 participants from the non-birth control group, who experience hormonal acne/frequent hormonal breakouts will provide photographs of the face for expert skin grading at baseline, week 12, week 20, and week 24 (if the study is continued until week 24). Questionnaires will be used to monitor changes in the menstrual cycle (regularity, frequency, predictability), bloating, fluid retention, weight gain, mood (mood swings, anxiety, mental clarity/focus, brain fog), pain, fatigue, acne, facial/bodily hair, and sleep quality. Expert skin grading will be carried out by a dermatologist to monitor changes in acne and skin clarity indicative of systemic effects of androgen excess. Likert scale responses will be statistically compared from baseline to each check-in. Participant responses on product feedback will be presented as % scores.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 70
Est. completion date April 15, 2024
Est. primary completion date April 15, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 36 Years
Eligibility Inclusion Criteria: - Female aged 18-36 - Diagnosed with PCOS in the last 5 years. - Has experienced at least two of the following: 1. Irregular menstrual periods or the absence of menstrual periods. 2. Excessive facial or body hair, thinning hair, or hair loss on the scalp, oily skin, and or acne. 3. Polycystic ovaries as determined by ultrasound. - Otherwise generally healthy (not living with any uncontrolled chronic disease) - Has concerns about irregular menstrual cycles and ovulation, mood swings, stress, tender breasts, food cravings, irritability, or low energy. - Following stable, consistent diet and exercise regimens, and willing to refrain from making any lifestyle changes that may affect their menstrual cycle for the duration of the study. - Willing to refrain from taking any other supplements that may target the menstrual cycle throughout the study period. - Willing and able to adhere to the study protocol, including taking supplements at the required times, completing questionnaires via the technology portal, and where appropriate sharing the required photographs. - Able to communicate in English. - Participants must provide written informed consent (ICF). - For the hormonal birth control group: must have been on the same hormonal birth control for the past 3 months and be willing to not make any changes to their hormonal birth control for the next 6 months. - For the non-hormonal birth control group: must have been off hormonal birth control for the past 3 months and be willing to stay off hormonal birth control for the next 6 months. - For the non-hormonal birth control group: Experience hormonal acne or frequent acne breakouts (a symptom of androgen excess). Exclusion Criteria: - Any pre-existing, unstable or uncontrolled medical or psychiatric illness. - Anyone who has been diagnosed with endometriosis, uterine fibroids, pelvic inflammatory disease, reproductive cancers, chronic liver disease, diverticular disease, colorectal cancer or previous history of colorectal cancer, chronic pancreatitis, adenomyosis, fibromyalgia, rheumatoid arthiritis, lupus, inflammatory bowel disease, diagnosed chronic uncontrolled migraines, chronic pelvic pain syndrome, multiple sclerosis, chronic fatigue syndrome. - Anyone who has undergone a hysterectomy, bilateral salpingo-oophorectomy, or any other gynecological medical or surgical treatment in the past 6 months. - Anyone with significant abnormalities in the physical or laboratory examination. This includes having renal or liver function more than twice the normal range. - Anyone with known severe allergic reactions that require the use of an epi-pen, or anyone who has any known allergy to any of the test product ingredients. - Women who are pregnant, breastfeeding or attempting to become pregnant. - Unwilling or unable to follow the study protocol. - Users of any medication, herbal remedy, or supplement that can affect the menstrual cycle, or anyone who has used Elix Daily Harmony or Cycle Balance in the past. - Anyone who has introduced a new medication, supplement or herbal remedies that target weight, skin (acne), mood, or menstrual cycle, in the last 3 months. - Smokers, or anyone who has smoked in the past 6 months. - Anyone with a history of substance abuse. - Anyone who has more than 3 alcoholic drinks per day. - Anyone with a BMI >35. - For the hormonal birth control group: anyone who has changed their hormonal birth control in the past 3 months, or who is planning to change it in the next 6 months. - For the non-hormonal birth control group: anyone who has been on hormonal birth control for the past 3 months, or who is planning to start using hormonal birth control in the next 6 months.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Elix Daily Harmony
Elix Daily Harmony is a clinical-strength, organic blend of hormone-balancing Traditional Chinese Medicine (TCM) herbs and adaptogens. Contains Angelica Sinensis, licorice, ginger, Bupleurum, Cyperus Rotundus, White Peony, Mint, Poria, Atractylodes, White Ginseng, Reishi, Rehmannia Root, and Astragalus. Participants should add 3 droppers full (half a teaspoon or 2.5 ml) of Elix Daily Harmony to their tea or other warm or room temperature beverage each morning, 1-2 hours after their first meal. The product should not be taken with iced drinks or with food.
Elix Cycle Balance
A tailored blend of medicinal herbs to holistically support menstrual symptoms by treating underlying imbalances. Participants should take 3 droppers full (half a teaspoon or 2.5 ml) of Elix Cycle Balance daily before bed with tea or other warm or room temperature beverage. The product should not be taken with iced drinks or with food.

Locations

Country Name City State
United States Citruslabs Santa Monica California

Sponsors (2)

Lead Sponsor Collaborator
Zenchi, Inc. Citruslabs

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To examine the effect of Daily Harmony and Elix Cycle Balance on menstrual cycle regularity and frequency. [Time Frame: Baseline to Week 24] Menstrual cycle frequency and regularity will be measured via self-reported questionnaire 24 weeks.
Primary To examine the effect of Daily Harmony and Elix Cycle Balance on acne as a symptom of hyperandrogenism. [Time Frame: Baseline to Week 24] Assessed via self-reported questionnaires using the validated acne quality-of-life scale. Participants will record their score using a 7-point Likert Scale, with 1 representing the most severe symptoms and 7 representing the least severe symptoms. 24 weeks
Primary To examine the effect of Daily Harmony and Elix Cycle Balance on acne measure via expert skin grading. [Time Frame: Baseline to Week 24] Expert skin grading at baseline and at the end of weeks 12, 20, and 24 will be carried out by a dermatologist and used as a digital biomarker to evaluate improvements in PCOS related skin health (acne/skin clarity). 24 weeks
Secondary To examine the effect of Daily Harmony and Elix Cycle Balance on PCOS-associated symptoms. [Time Frame: Baseline to Week 24] Study-specific surveys will be used to assess the severity and incidence of common PCOS symptoms, including sleep quality bloating/fluid retention, weight gain, fatigue, mood swings, mental clarity/focus/brain fog, anxiety and pain. Participants will record their score using a 5-point Likert Scale, with 1 representing the most negative outcome and 5 representing the best outcome (no symptoms). 24 weeks
See also
  Status Clinical Trial Phase
Completed NCT03142633 - MicroRNA as Biomarkers for Development of Metabolic Syndrome in Women With Polycystic Ovary Syndrome
Completed NCT06158932 - A Single Group Study to Evaluate the Effects of a Myo-Inositol and D-Chiro Inositol Supplement on Symptoms Associated With Polycystic Ovary Syndrome and Hormone Imbalance N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Active, not recruiting NCT02500147 - Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Phase 4
Completed NCT04932070 - Berberine and Polycystic Ovary Syndrome N/A
Suspended NCT03652987 - Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
Completed NCT03480022 - Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS Phase 3
Active, not recruiting NCT03043924 - Functional Study of the Hypothalamus in Magnetic Resonance Imaging (MRI) in Polycystic Ovary Syndrome (PCOS) N/A
Completed NCT05246306 - Aerobic Capacity and Physical Fitness Level of Adolescents With PCOS
Completed NCT05981742 - Effects of Combined Metformin and Cabergoline in Comparison With Metformin Only Therapy on Ovarian and Hormonal Activities in Iraqi Patients With PCOS Phase 2
Completed NCT05702957 - Letrozole vs Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovarian Syndrome Phase 2/Phase 3
Completed NCT05029492 - Effect of Visceral Manipulation on PCOS N/A
Completed NCT02924025 - Motivational Interviewing as an Intervention for PCOS N/A
Not yet recruiting NCT02255578 - Endobarrier Treatment in Women With PCOS Phase 3
Withdrawn NCT01638988 - Clomifene Citrate Versus Metformin in First-line Treatment of Infertility in Patients With Polycystic Ovary Syndrome and a Resistance to Insulin Phase 3
Not yet recruiting NCT00883259 - Metformin and Gestational Diabetes in High-risk Patients: a RCTs Phase 4
Completed NCT02098668 - Mathematical Model for the Human Menstrual Cycle, Endocrinological Diseases and Fertility Treatment-PAEON N/A
Completed NCT01462864 - Development of a Structured Education Programme for Women With Polycystic Ovary Syndrome N/A
Recruiting NCT01431352 - Letrozole Versus Chinese Herbal Medicine on Polycystic Ovary Syndrome (PCOS) N/A
Completed NCT00989781 - Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome N/A